

New Test System for Serine/Threonine Protein Kinase Inhibitors Screening: *E. coli* APHVIII/Pk25 design.

O.B. Bekker¹, M.G. Alekseeva¹, D.I. Osolodkin², V.A. Palyulin², S.M. Elizarov³, N.S. Zefirov², V.N. Danilenko^{1*}

¹Vavilov Institute of General Genetics, Russian Academy of Sciences

²Lomonosov Moscow State University, Department of Chemistry

³Bach Institute of Biochemistry, Russian Academy of Sciences

*E-mail: valerid@rutenia.ru

Received 28.06.2010

ABSTRACT An efficient test system for serine/threonine protein kinase inhibitors screening has been developed based on the *E. coli* protein system APHVIII/Pk25. Phosphorylation of aminoglycoside phosphotransferase VIII (APHVIII) by protein kinases enhances resistance of the bacterial cell to aminoglycoside antibiotics, e.g. kanamycin. Addition of protein kinase inhibitors prevents phosphorylation and increases cell sensitivity to kanamycin. We have obtained modifications of APHVIII in which phosphorylatable Ser146 was encompassed into the canonical autophosphorylation sequence of *Streptomyces coelicolor* Pk25 protein kinase. Mutant and wild-type *aphVIII* were cloned into *E. coli* with the catalytic domain of *pk25*. As a result of the expression of these genes, accumulation of corresponding proteins was clearly observed. Extracted from bacterial lysates, Pk25 demonstrated its ability to autophosphorylate. It was shown that variants of *E. coli* containing both *aphVIII* and *pk25* were more resistant to kanamycin than those carrying only *aphVIII*. Protein kinase inhibitors of the indolylmaleimide class actively inhibited Pk25 and reduced cell resistance to kanamycin. Modeling of APHVIII and Pk25 3D structures showed that pSer146 is an analog of phosphoserine in the ribose pocket of protein kinase A. Pk25 conformation was similar to that of PknB of *Mycobacterium tuberculosis*. Potential indolylmaleimide inhibitors were docked into the ATP-binding pocket of Pk25. The designed test system can be used for the primary selection of ATP-competitive small molecule protein kinase inhibitors.

KEYWORDS serine/threonine protein kinases, indolylmaleimides, protein kinase inhibitors screening, bacterial test system, *Streptomyces*

Serine/threonine protein kinases (STPK) are a group of universal regulators of the cellular metabolism in eukaryotes [1-3]. They play leading roles in the regulation of apoptosis, proliferation and differentiation, cellular transport, etc. It has been shown that kinase malfunction can be associated with various human diseases, such as diabetes [4], schizophrenia [5], cardiovascular disorders [6,7], and immune dysfunctions [8]. Over the past decades, the search for new targeted modulators (inhibitors) of protein kinases, that are considered as potential drugs, has been intensive [9-11].

Eukaryotic type serine/threonine protein kinases were found in bacteria, including human pathogens [12]. It was shown that STPKs participate in virulence, bacterial biofilm formation, tolerance, and persistence of pathogenic microorganisms. STPKs were shown to play the key role in the virulence of *Streptococcus pneumoniae*, *Mycobacterium tuberculosis*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and certain other pathogens [12-14]. It is established that STPKs par-

ticipate in the modulation of antibiotic resistance in *M. tuberculosis* [15]. Intensive STPK inhibitors screening is currently under way [16-19].

We have developed a test system [20] for prescreening of STPK inhibitors based on the newly constructed strain *Streptomyces lividans* TK24 (66) APHVIII+. The key part of this test system is type VIII aminoglycoside phosphotransferase (APHVIII), an enzyme that inactivates aminoglycoside antibiotics. Gene *aphVIII*, which is isolated from *Streptomyces rimosus*, was cloned into *S. lividans* TK24 (66) and expressed. Importantly, the activity of APHVIII *S. rimosus* is dependent on phosphorylation by endogenous STPKs [21]. Phosphorylation of APHVIII confers *Streptomyces* cells resistance to aminoglycoside antibiotics, while inhibitors of STPK render cells more sensitive to aminoglycosides [20]. Alteration of the cellular sensitivity to aminoglycoside antibiotics in the presence of STPK inhibitors allows to perform primary screening of these inhibitors. Upon annotation of the genome of the *S. coelicolor* A3(2) strain (NC_003888), which is close to *S. lividans* TK24

(66) (ACEY01000000), 34 STPKs were identified. At least one of them – Pk25 (NCBI Reference Sequence: Protein NP_628936.1) – is able to phosphorylate APH-VIII [22]. In order to rule out a nonspecific action of STPK inhibitors on the other STPKs of *S. lividans* TK24 (66) that are presumably able to phosphorylate APHVIII, the catalytic domain of Pk25 kinase and APHVIII were hosted in *Escherichia coli*. The genome of *E. coli* does not contain its own eukaryotic STPKs, which makes the test system more sensitive and allows the screening of inhibitors that are specific to Pk25 and its homologous enzymes [23].

EXPERIMENTAL PROCEDURES

Strains: *S. coelicolor* A3(2) (Russian Collection of Pathogenic Microorganisms, Moscow), *S. lividans* TK24 (66) APHVIII+ (GenBank ACEY01000000), *E. coli* DH5 α : F⁻, Φ 80 Δ lacZ Δ M15, Δ (lacZYA-argF), U169 (Promega); BL21(DE3): F⁻, dcm, ompT, hsdS(r_B⁻m_B⁻), gal(DE3) (Novagen).

Plasmids: pET16b, pET22b and pET32a (Novagen).

Media: *S. coelicolor* A3(2) and *S. lividans* TK24 (66) APHVIII+ strains were grown on YSP and YEME media [24]. *E. coli* strains were grown on Luria broth (L-broth), NZCYM, M9 supplemented with 1.5 % glycerol (1 L): 6 g Na₂HPO₄, 3 g KH₂PO₄, 0.5 g NaCl, 1 g NH₄Cl, pH 7.4, 2 mL 1 M MgSO₄, 15 mL glycerol. Ampicillin (100 μ g/ml) was added to the media to ensure the survival of plasmid-containing cells. Protein expression was induced by IPTG (1 mM).

Molecular cloning: Total DNA was isolated from *S. coelicolor* A3(2) and *S. lividans* TK24 (66) APHVIII+ strains according to [24]. Isolation of plasmid DNA, preparation of competent *E. coli* cells, transformation and analysis of recombinant plasmids was performed according to standard protocols [25]. DNA amplification by PCR was carried out by the “Amplification” kit (Dialat Ltd.) on the Tertsik TP4-PCR01 amplifier (DNA-tekhnologiya). The temperature cycle was designed according to primer length and composition. Oligonucleotides were purchased from Syntol (see Table 1). The DNA sequence was determined according to Sanger. Nucleotide sequences were compared with BLAST (<http://www.ncbi.nlm.nih.gov/blast>).

Protein electrophoresis was carried out in 12% polyacrylamide gels under denaturing conditions, as described earlier [21]. Bacterial cells containing constructed plasmids were grown on a NZCYM liquid medium supplemented with ampicillin (150 μ g/ml) at 34°C up to an optical density equal to 0.6 (~1,5 h). Expression of the Pk25 catalytic domain was induced by the addition of IPTG (final concentration 1 mM). Cells were grown at 28°C for 4 h, harvested and re-suspended in a buffer containing 62.5 mM TrisHCl, pH 6.8; 5% glycerol; 2%

β -mercaptoethanol; 0.1% SDS; and Bromophenol Blue. Cells were lysed by boiling for 10 min in the above-mentioned buffer and subjected to electrophoresis in polyacrylamide gels. Approximately 25 μ g of the protein was loaded into each well in the gel. Electrophoregrams were scanned by laser densitometer Ultrosan 2205 LKB. A protein fraction of *E. coli* BL21(DE3) cells transfected with the empty vector was used as control.

Isolation of the catalytic domain of Pk25 cloned into *E. coli* cells. Cells were destroyed by sonication in a buffer containing 20 mM TrisHCl, pH 7.8, 10 mM 2-mercaptoethanol, 300 mM NaCl, and 1 mM PMSF, or in the same buffer supplemented with 8 M urea. Cell debris and other undissolved material was removed by centrifugation at 20,000g in 20 min. Fractions of soluble proteins were loaded onto a Ni-NTA agarose column (Qiagen) which was washed by the above-described buffer containing 50 mM imidazole pH 6.0. The protein was eluted by the buffer with imidazole concentration increasing from 0.05 M up to 0.5 M [20]. Protein fractions were analyzed by SDS-PAGE.

Analysis of autophosphorylation of isolated protein by catalytic domain of Pk25 *in situ* was performed after separation of the protein under denaturing conditions. Re-naturation of the kinase in gel was carried out according to Kashemita and Fujisawa [26]. Gels containing the protein were intensively washed in 50 mM TrisHCl, pH 7.8, with 25% 2-propanol and 8 M urea in order to remove SDS. Following that, protein re-naturation was carried out by washing gels in buffer A: 50 mM TrisHCl, pH 7.8 and B: 50 mM TrisHCl, pH 7.8, 100 mM NaCl, 6 mM β -mercaptoethanol, 5 mM MgCl₂, and 1 mM CaCl₂. After re-naturation, the gels were incubated in the presence of 50 μ Ci/ml [γ -³²P]ATP (7000 Ci/mM, Phosphor, Russian Federation) in the buffer for the analysis of kinase activity [21]. The gels were fixed and stained in 40% TCA, washed in 5% acetic acid, dried and autoradiographed by exposure to a Kodak X-Omat AR film.

Cloning into expressional vectors pET32a, pET22b, and pET16b. Gene *pk25* of the *S. coelicolor* A3(2) strain and the gene of *S. lividans* TK24 (66) were cloned into *E. coli* in pET32a plasmid at EcoRI and HindIII (primers Pk25EN and Pk25C) (Table 1). The gene of the catalytic domain of *pk25* of the *S. coelicolor* A3(2) strain was cloned into *E. coli* in pET22b plasmid at NdeI and HindIII (primers Pk25CN and Pk25CC). The modified gene *aphVII* was cloned into *E. coli* in pET16b plasmid at NdeI and XhoI (primers *AphN* and *AphC*). The gene of the catalytic domain of *pk25* of the *S. coelicolor* A3(2) strain was cloned into *E. coli* in pET16b + *aphVIII146-S* with the non-modified phosphorylation site of APHVIII, pET16b + *aphVIII146-1*, pET16b + *aphVIII146-2*, and pET16b + *aphVIII146-3* with modified phospho-

rylation sites at the BamHI (primers Pk25NBgl and Pk25CBgl).

Cloning of the nucleotide sequence of the *pk25* catalytic domain was performed in the pET22b vector at NdeI–HindIII restriction sites (primer Pk25CN homologous to the N-terminal region of the catalytic domain, and primer Pk25CC homologous to the C-terminal region of the catalytic domain). The DNA sequence of the catalytic domain was amplified using total DNA of *S. coelicolor* as a template. The PCR product was purified from the agarose gel, then sequenced and cloned into the pET22b vector at the NdeI and HindIII. *E. coli* DH5a cells were transformed by the resulting ligase mix, and screening of recombinant clones was carried out by PCR using standard primers T7prom and T7term. Plasmid DNA was isolated from selected transformants, and the obtained recombinant plasmids were sequenced and subjected to restriction analysis to verify the presence of the insert. Then, the plasmids were used for the transformation of *E. coli* BL21 (DE3) cells.

Site-directed mutagenesis of Ser146 in aminoglycoside phosphotransferase APHVIII was carried out according to Nelson [27]. In order to obtain the mutant variant 1 (amino acid substitutions Ser146Thr, Glu144Thr, Asp148Ser), the primers APH 146-1(+) and APH 146-1(-) (Table 1) were used. The primers

APH146-2(+) and APH146-2(-) were used to obtain the mutant variant 2 (Glu144Thr, Asp148Ser, Glu150Ser). The mutant variant 3 represents substitution Ser146Thr, which was introduced using the APH146-T(+) and APH146-T(-) primers.

AphN and AphC corresponding to the 5'- and 3'-terminal fragments of the *aphVIII* gene were used as flanking primers.

The obtained mutant PCR fragments were sequenced to verify the nucleotide substitutions and cloned at the NdeI and BamHI restriction sites into the high-copy number plasmid pET16b containing T7 phage transcriptional and translational regulatory elements in the same reading frame with the ATG codone of the gene of interest. This plasmid was used for the transformation of *E. coli* DH5a cells, and screening of the recombinant clones was carried out by PCR using T7prom and T7term primers. The selected transformants were used for purification of plasmid DNA, which was re-sequenced to ensure the substitutions.

Determination of resistance to kanamycin in selected transformants of *E. coli* BL21(DE3). *E. coli* BL21(DE3) clones containing genes of either native or modified *aphVIII* or *aphVIII* and *pk25* in the pET16b vector were used for the analysis. The clones resistant to ampicillin (100 µg/ml) were transferred on the plates with the LB-medium containing various concentrations

Table 1. Primers which were used in the present work*

Primer	Restriction site	Primer structure, 5'–3'
Pk25EN	EcoRI	ATCCGAATTATGGCACGGAAGATCGGCAG
Pk25C	HindIII	CCGCAAGCTTGGTGCCGTTGCCGGAACCG
Pk25CN	NdeI	TCGTCATATGCGTTACC GGCTCCATGAGCGGC
Pk25CC	HindIII	CCGCAAGCTTCATCCGCTGGGCCGACGCCG
Pk25NBgl	Bgl II	TTTTAGATCTAATAAGGAGATATACATGTACCGGCTCCATGAGCGGCT RBS beginning of <i>pk25</i> catalytic domain
Pk25CBgl	Bgl II	CCG CAG ATC TAT CCG CTG GGC CGA CGC CGC
T7prom	—	TTAATACGACTCACTATAGG
T7term	—	CTAGTTATTGCTCAGCGG
APH 146-1(+)	—	GCTGTCGCTACAGGGACGGTCAGCTTGGAGGATCTGGAC
APH 146-1(-)	—	GTCCAGATCCTCCAAGCTGACCGTCCCTGTAGCGACAGC
APH 146-2(+)	—	GCTGTCGCTACAGGGAGCGTCACCTTGTCCGATCTGGACGAG
APH 146-2(-)	—	CTCGTCCAGATCCGACAAGGTGACGCTCCCTGTAGCGACAGC
APH 146-T(+)	—	GTCGCTGAAGGGACCGTCCGACTTGGAG
APH 146-T(-)	—	CTCCAAGTCGACGGTCCCTTCAGCGAC
AphN	NdeI	TTTTCATATGGACGATGCGTTGCGTGC
AphC	BamHI	TTTTGGATCCTCAGAAGA ACTCGTCCAAC

Restriction sites are given in **bold, nucleotide substitutions are underlined.

of aminoglycoside antibiotic kanamycin and IPTG as the inducer. The growth of colonies was monitored after 25 hours of incubation at 37°C.

Determination of activity of protein kinase inhibitors in the bacterial test system. Inhibitor activity was determined using paper discs. The paper discs soaked with antibiotic or an antibiotic/inhibitor mixture were placed on the surface of agar plates, and the size of the zone of bacterial growth suppression was measured. Test system: *E. coli* BL21(DE3)APHVIII/Pk25. Bacteria grown on agar plates supplemented with ampicillin were washed off into a liquid LB-medium and grown overnight at 37°C. Then the cells were pelleted (4,000 rpm, 10 min) and re-suspended in a liquid M9 medium. Bacterial suspension was mixed up in a 1:1 ratio with a melted M9-agar medium containing ampicillin and IPTG as the inducer. The mixture was poured onto Petri dishes with a M9-agar medium containing ampicillin and IPTG. Ampicillin is necessary for maintaining the plasmid in the *E. coli* cells. Paper discs containing kanamycin or kanamycin plus the kinase inhibitor were placed on the surface of the agar plates and incubated for 16 hours at 37°C.

Modeling of Pk25 catalytic domain structure. X-ray structures of kinase from *M. tuberculosis PknB* (PDB entries PDB [28]: 1MRU [29], 1O6Y [30], 2FUM [31], 3F61 [32], 3F69 [32]) were used as templates for the model building. Amino acid sequences of the template protein were extracted directly from structural files; the sequence of *S. coelicolor* A3(2) was taken from GenBank (access code 21223157 [33]). The catalytic domain was annotated according to homology. Alignment of amino acid sequences was carried out using the ClustalX 2.0.11 [34] software. The modeling was performed with the Modeller 9v5 [35] program. Thirty-five models of the catalytic domain were generated, and each of them was optimized by simulated annealing. The best model was selected according to the DOPE scoring function (Modeller software) and PROCHECK validation score [36]. Further optimization was performed in SYBYL 8.0 [37]; all hydrogen atoms were added to the models, and the energy was minimized in the Tripos force field [38] by the Powell method.

Modeling of the APHVIII catalytic domain structure was based on the X-ray structure of its closest homologue APH(3')-IIa (PDB entry 1ND4 [39], 36% identity of amino acid sequence) in complex with kanamycin. The modeling method is similar to the one described above: the only difference was that 50 models were generated in each case.

Docking of inhibitors into the Pk25 model was performed using the Autodock 4.1 [40] software. The structures of the inhibitors were drawn by SYBYL 8.0 and optimized with the MMFF94 force field [41]. Docking

preparation was carried out in MGLTools 1.5.4 [42] according to standard recommendations. Generation of the grids and docking were performed using default parameters, while the position of the docking grid was chosen to include all essential amino acid residues of the ATP-binding site. During docking of each ligand, 100 runs of the genetic algorithm were performed. Docking results were grouped into clusters using a threshold value of RMSD equal to 2.0 Å. The results were analyzed in MGLTools 1.5.4.

RESULTS

Cloning and comparison of full-size genes of serine/threonine protein kinase *pK25* from *S. coelicolor* and *pK25 S. lividans*.

According to genome sequencing data, the gene of the *pK25* kinase from *S. lividans* TK24 (ACEY01000000) and the gene of *pK25* kinase from *S. coelicolor* share 99.8% homology and differ only in 6 base pairs, including an insertion of C at position 664. The presence of this insertion leads to the shift of the reading frame in the catalytic domain sequence. In order to compare the kinases of interest from our collection of *S. coelicolor* A3(2) and *S. lividans* TK24 (66) strains, we cloned and sequenced the genes of these kinases. To isolate *pK25* kinase genes from the genomes of *S. coelicolor* and *S. lividans*, two oligonucleotides containing HindIII and EcoRI were synthesized (*pK25EN*, homologous to the N-terminal part of the gene; and *Pk25C*, complementary to the C-terminal part of the gene, Table 1). Amplification from total DNA of *S. coelicolor* and *S. lividans* yielded the needed DNA fragments, which were cloned into the pET32a vector at the HindIII and EcoRI and introduced into *E. coli* DH5a cells. Sequencing verified that the obtained DNA fragments contained the *pK25* gene. Comparison of the genes from *S. coelicolor* and *S. lividans* revealed nucleotide substitutions at positions 123, 237, 279, 435, and 963 starting from the first ATG of the structural region of the *S. lividans pK25* gene. These nucleotide substitutions do not lead to amino acid substitutions in the corresponding proteins. Therefore, the amino acid sequences of the full-size *pK25* genes from *S. coelicolor* and *S. lividans* were shown to be identical.

Cloning and expression of the *S. coelicolor* Pk25 catalytic domain nucleotide sequence into pET22b vector.

Two oligonucleotides (*Pk25CN* and *Pk25CC*) containing NdeI and HindIII were synthesized for the cloning (Table 1). The fragment obtained during amplification was digested with the relevant restriction endonucleases and cloned into the pET22b vector that was introduced into *E. coli* DH5a cells. After resequencing, the obtained vectors were introduced into the *E. coli* BL21(DE3) strain used for protein overexpression.





Fig 1. a – Electrophoresis of soluble protein fraction of *E. coli* BL21(DE3). 1 – marker, 2 – control protein fraction of *E. coli* BL21(DE3) pET22b, 3-10 – *E. coli* clones containing pET22b-pk25. (*- protein fraction of Pk25 catalytic domain). b – Electrophoresis of isolated protein fraction of *S. coelicolor* Pk25 catalytic domain in PAAG: 1 – autoradiogram autophosphorylate Pk25 catalytic domain, 2- coloring coomassie brilliant blue.

In order to study the expression of the catalytic domain of Pk25 kinase in *E. coli* cells, we set up gel electrophoresis of a fraction of soluble cellular proteins under denaturing conditions. A protein fraction from *E. coli* BL21(DE3) transformed with an empty pET22b vector were used as a control. Electrophoresis showed that *E. coli* cells transformed with the plasmid carrying the gene of the pk25 catalytic domain containing an additional protein fraction of 28 kDa (Fig 1a) as compared with the control cells. This value coincides with the calculated molecular weight (27.8 kDa) of the catalytic domain of Pk25 kinase from the *S. coelicolor* A3(2) strain. Scanning revealed that the additional fraction represents about 3.5% of the total cellular protein.

Modeling of the Pk25 catalytic domain 3D structure.

The key structural features of Pk25 are revealed by the model, which is very close to the structure of the template protein PknB *M. tuberculosis* due to the close similarity of the sequences (Fig. 2a). The net charge of the catalytic domain is equal to -3. The most obvious differences between the model and the template are observed in the region of helix C (an insertion of four amino acid residues in Pk25), in the loop between fragments $\beta 4$ and $\beta 5$ (deletion of four amino acid residues in Pk25), and in the region of the $\eta 3$ helix (deletion of five amino acid residues in Pk25). Conformation of the activation loop differs from that in the template due to its flexibility. However, the mentioned differences do not affect the orientation of amino acid residues in the ATP-binding site. There are five amino acid residues in the ATP-binding pocket of Pk25 that differ from the corresponding residues of PknB (Fig. 2b): Val72Ile, Ile90Met, Tyr94Leu,

Met145Leu, and Met155Thr (numeration of the PknB sequence is used). The former three substitutions are relatively conserved and should not seriously affect the interaction with the inhibitor. Substitution Tyr94Leu is located in the hinge region, so ligands interact with the backbone of this residue but not with its sidechain. The latter two substitutions are not conservative and, therefore, should influence the interaction with the inhibitor. In particular, these substitutions increase the accessible volume of the binding pocket. Finally, an additional hydroxy group appears in this region due to the introduction of a threonine residue at position 155.

Analysis of autophosphorylation of the Pk25 activation loop.

A protein fraction of the Pk25 catalytic domain was isolated from lysed *E. coli* cells by means of chromatography on a His-binding resin under either native conditions or in the presence of 8M urea. After electrophoresis, we were able to analyze its intracellular localization and autophosphorylation *in situ*. The catalytic domain of Pk25 was absent in the fraction of salt-soluble cellular proteins. This recombinant protein is present in the fraction of insoluble cellular proteins and can be dissolved in the presence of urea, as was done. After separation by electrophoresis, the molecular mass of the studied fragment was determined as equal to 28 kDa, which is very close to the calculated value. In the presence of [γ - 32 P] ATP, the protein accumulates labeled phosphate (Fig. 1b). Separation of the protein components by gel electrophoresis excludes any possible interfering influences of other proteins. Over all, the obtained data indicate that the isolated catalytic domain of Pk25 kinase is an enzy-





Fig 2. The model of Pk25 3D structure. *a* — Superimposition of the template structure PknB *M. tuberculosis* (green) and Pk25 model (colored by secondary structure type). *b* — ATP-binding pockets of PknB (colored by atom type) and Pk25 (orange); nonconservative amino acid residues are shown as sticks. *c* — binding mode of LCTA-1425 with Pk25. The kinase VdW surface is colored according to hydrogen bond donor/acceptor properties (red — donor, blue — acceptor).

Fig 3. The model of APHVIII 3D structure. *a* — Superimposition of the template structure APH(3')-IIa (PDB ID 1ND4, orange) and APHVIII model (colored by secondary structure type). *b* — Amino acid residues in the activation loop of wild-type APH-VIII (carbons are colored orange) and 146-1 mutant (grey carbons).



matically active protein and undergoes autophosphorylation. Localization of the Pk25 catalytic domain in the fraction of insoluble cellular proteins does not contradict the possibility of its autophosphorylation during expression and, likewise, does not exclude its activity towards both soluble and insoluble proteins. These results are in agreement with the data obtained on the catalytic domains of *Streptomyces* and *Mycobacterium* protein kinases [43–45]. It was shown that phosphorylation in the activation loop of STPK occurs at a Ser residue. Analysis of the substrate specificity of STPK from *M. tuberculosis* showed that the highest phosphorylation efficiency was observed at the regions that are similar to the autophosphorylation sites of the kinase [46].

Modeling of the aminoglycoside phosphotransferase VIII 3D structure

The model of the APHVIII catalytic domain structure closely resembles the template protein APH(3')-IIa (Fig. 3a). The two structures are most similar in the sites of the ATP and kanamycin binding, as well as in the activation loop. The small insertions in the APHVIII sequence are located in the structurally nonconserved regions of the loops, and between various elements of the secondary structure they are unlikely to seriously affect the 3D pattern of the polypeptide chain. The physico-chemical properties and conformations of the crucial amino acid residues that form the ATP and kanamycin binding sites also correspond within the template and

Table 2. Modifications of phosphorylation site Ser-146 in APHVIII

Native enzymes and modified species of APHVIII	Phosphorylation sites and their modifications*
Pk25	ATTLTESGSFVG
APHVIII	AVAEGS ₁₄₆ VDLED
APHVIII146-1	AVAT <u>GT</u> ₁₄₆ VSLED
APHVIII146-2	AVATGS ₁₄₆ VSLSD
APHVIII146-3	AVAEG <u>T</u> ₁₄₆ VDLED
APHVIII146-4	AVAEGA ₁₄₆ VDLED

*Amino acid substitutions are underlined.

the model. The structure of APHVIII146-1 almost fully matches that of wild-type protein. Differences are observed in the activation loop and are unlikely to affect the global conformation of the protein (Fig. 3b).

The phosphorylation site of APHVII (Ser146) is an homologue of phosphoserine in the ribose pocket of PKA-type serine/threonine kinases [47]. A molecular dynamics simulation of unphosphorylated APHVIII in complex with kanamycin (with bound ATP and two Mg²⁺ ions) revealed pronounced alterations of the enzyme's structure, such as weakening of the contact between the N- and C-terminal domains. [48, 49].

Modification of Ser146 region of aminoglycoside phosphotransferase APHVII – the site of phosphorylation by Pk25 kinase

The autophosphorylation site in the Pk25 activation loop was determined through a comparison with the corresponding region of *M. tuberculosis* PknB [50]:

PknB DFGI ARAIAD SGNSVTQTAAVGTAQYLSPE
 Pk25 DFGV AQVAGA TTLTESGSFVGSPEYTAPE

To optimize the test system *E. coli* APHVIII/Pk25, we modified the potential phosphorylation site AVAEGS₁₄₆VDLED in the APHVIII activation loop. The objective was to make site Ser146 APHVIII more structurally similar to the Pk25 autophosphorylation site TTLTESGSFVG. To achieve that, we modified the amino acid residues in the vicinity of APHVIII Ser146 (Table 2), introducing the underlined amino acid substitutions. The obtained mutant variants of the gene *aphVIII146-1*, *aphVIII146-2*, *aphVIII146-3*, and *aphVIII146-4* were ligated into the pET16b vector at the NdeI-BamHI and introduced into *E. coli* DH5a. After resequencing, the plasmids pET16baphVIII m1 (Fig. 4a) were used for the transformation of *E. coli* BL21(DE3).

Expression of all variants of APHVIII in *E. coli* was checked by gel electrophoresis of soluble cellular proteins under denaturing conditions.

E. coli cells containing pET16baphVIII plasmid expressed a 31 kDa protein, which corresponded to the calculated molecular mass of APHVIII equal to 31.5 kDa.

Creation of a construct containing genes of aminoglycoside phosphotransferase *aphVII* and protein kinase *pk25*

Amplification of *pk25* was performed with the primers Pk25NBgl and Pk25CBgl (Table 1) from the DNA of the plasmid vector pET22b-*pk25*. The Pk25NBgl primer contained a ribosome-binding site (RBS) and an ATG codone for the catalytic domain of protein kinase Pk25. The nucleotide sequence of *pk25* was amplified and digested by BglII and then ligated into the pET16baphVIII m1 containing the previously described variants of *aphVIII* at the BamHI. At the first stage, the presence of the insert was checked by amplification with T7 primers. At the second stage, the clones were selected by amplification with AphN and Pk25CC primers (table 1) according to the presence and the size of the insert. After resequencing, pET16APC plasmids (Fig. 4b) were used for the transformation of *E. coli* BL21(DE3). Expression of genes *aphVIII* and *pk25* after induction was checked by gel electrophoresis. In the first four variants (Fig. 5) (lanes 2-5), additional fractions of APHVIII are observed. Lane 6 contains an additional fraction of *pk25*, while lanes 7-10 contain both a 31.5 kDa fraction and a 28 kDa fraction, which are APHVIII and Pk25, respectively. Mass-spectrometry was used to verify the protein fraction on lane 7. It was shown that the heavier fraction contains APHVIII (AA Y27879.1 aminoglycoside-O-phosphotransferase VIII). The other fraction contains the catalytic domain of Pk25 (1100219




Fig 4. Vectors: a – pET16baphVIII m1 containing *aphVIII* mutant variants: *aphVIII146-1*, *aphVIII146-2*, *aphVIII 146-3*, *aphVIII146-4* and primary *aphVIII146-S*. b – pET16APC containing *pk25* and *aphVIII* mutant variants *aphVIII146-1*, *aphVIII146-2*, *aphVIII146-3*, and primary *aphVIII146-S*.

NP_628936.1 serine/threonine protein kinase *S. coelicolor* A3(2)).

Analysis of kanamycin resistance in *E. coli* BL21(DE3) variants containing different modifications of *aphVIII* and their combinations with *pk25*.

Resistance of all constructs to aminoglycoside antibiotic kanamycin was studied (Table 3). The BL21(DE3) strain containing the plasmid pET16b encoding gene *aphVIII* was resistant to kanamycin (325 µg/ml).

The substitutions contained in the APHVIII146-1 variant led to a 48% decrease in resistance. In APH-

VIII146-2, resistance underwent a 54% decrease. The level of resistance in APHVIII146-3 containing the Ser(146)Thr substitution remained unchanged. In the case of the Ser(146)Ala substitution (APHVIII146-4), which causes the full inactivation of phosphorylation at Ser146, a 70% decrease in kanamycin-resistance was observed. The level of activity of APHVIII146-4 *in vitro* corresponds to the obtained data - the mutant variants exhibited a level of activity equal to 30% of that in wild type [51]. All constructs containing APHVIII with Pk25 showed a higher level of activity. We observed a 91% increase in kanamycin resistance in the case of APHVIII146-1/Pk25, an 83% increase in the case of APHVIII146-2/Pk25, and a 23% increase in the case of the initial construct APHVIII/Pk25, as well as in that with the Ser(146)Thr substitution.

Docking of indolylmaleimide inhibitors into the Pk25 model

The constructed test system *S. lividans*APHVIII+ has been used earlier for the screening of various chemical substances such as benzodiazines, benzophthalazines, cyclopentendions, indolylmaleimides, pyrazoles, thiazoles, thiazoltetrazines, etc. (unpublished data). A number of indolylmaleimide compounds that exhibit inhibitory activity towards protein kinases were identified. In order to propose the binding mechanisms of these substances, we carried out a molecular docking study. The results suggest that the inhibitors selected in the *S. lividans* TK24 (66) APHVIII/STPK test system (LCTA-1385, LCTA-1398, LCTA-1425 [20], bis-indolylmaleimide-1 [52]) can potentially interact with the ATP binding site of Pk25.

Docking of these inhibitors into the Pk25 model reveals conservative interactions between the maleimide




Fig 5. Electrophoresis of *E. coli* BL21(DE3) proteins including Pk25 catalytic domain, APHVIII: 1 – marker, 2 – primary APHVIII146-S fraction, 3 – APHVIII146-1 fraction, 4 – APHVIII146-2, 5 – APHVIII146-3, 6 – Pk25 catalytic domain, 7 – APHVIII146-S /Pk25 fractions, 8 – APHVIII146-1/Pk25, 9 – APHVIII146-2/Pk25, 10 – APHVIII146-3/Pk25. *E. coli* BL21 (DE3) pET22b/pk25 and *E. coli* BL21 (DE3) pET16baphVIII protein fractions analyzed as a negative control.




Fig. 6. Bacterial test-system *E. coli aphVIII /P_{k25}* for screening of inhibitors of serine-threonine protein kinases. **a** – The principle of the test-system: phosphorylation of Ser-146 P_{k25} in APHVIII leads to kanamycin-resistance in *E. coli*; addition of inhibitor prevents phosphorylation and reduces kanamycin resistance. **b** – Validation of the test-system with application of Bis-1 and Bis-5 as classical inhibitors [52]: addition of Bis-1 leads to the increase in the zone's size.

moiety and the backbone of the kinase (Fig. 2c). The inhibitors bis-indolylmaleimide-1 (Bis-I) and LCTA-1425 form two hydrogen bonds – one between the carbonyl oxygen atom of the maleimide moiety and the amide hydrogen of Val96, and another one between the imide hydrogen atom of the maleimide moiety and the carbonyl oxygen of Glu94. Inhibitors LCTA-1385 and LCTA-1398 were shown to form only the former hydrogen bond, since the hydrogen atom of the maleimide moiety is substituted in their molecules. Therefore, the estimated energy of interaction between P_{k25} and the latter two inhibitors is 1 kcal/mol less than that for the first two compounds. However, in both cases the interaction between the kinase and inhibitor is considered favorable.





Choice and validation of *E. coli* APHVIII/P_{k25}-based test system

Earlier we constructed and validated [20, 53, 54] a test system based on *S. lividans* TK24 (66) APHVIII/STPK [20]. The effect registered in this system was based on the cumulative action of the antibiotic kanamycin and a STPK modulator in a sub-inhibiting concentration [20] that resulted in the appearance of or increase in a zone of growth inhibition of the indicator culture. The size of the no-growth zone allowed to roughly estimate the efficiency of the STPK inhibitor [20]. That is why the range of changes of the resistance level to kanamycin, which is determined by various constructions of APHVIII, is of crucial importance. Based on this consideration, APHVIII146-1 is more favorable; so, in fur-

Table 3. Kanamycin resistance of *E. coli* BL21(DE3) strain containing various APHVIII species.

Name	Modified constructs APHVIII	Kanamycin resistance of <i>E. coli</i> , , µg/ml	
		APHVIII	APHVIII+P _{k25}
146-S	AVAEGS ₁₄₆ VDLED	325±5	400±10
146-1	AVATGT ₁₄₆ VSLED	170±10	325±5
146-2	AVATGS ₁₄₆ VLS _D	150±10	275±10
146-3	AVAEGT ₁₄₆ VDLED	325±5	400±10
146-4	AVAEGA ₁₄₆ VDLED	100±5	-

Table 4. Dependence of *E. coli* APHVIII146-1/Pk25 kanamycin resistance on various STPK inhibitors.

Known indolymaleimide inhibitors of STPKs.	Structure	Subinhibiting concentration, nmol/disc	Inhibition zone in <i>E. coli</i> APHVIII146-1/Pk25 test-system In the presence of kanamycin and inhibitor, mm
Bis-1		700	13.0
LCTA-1425		125	12.0
LCTA-1398		250	13.0
LCTA-1385		125	12.0

Note. Kanamycin-caused inhibition (5 mg/disc) zone size is 10 mm. Kanamycin resistance of *E. coli* strain containing APHVIII146-1 and Pk25 was determined by means of the paper disc method as described in "Experimental procedures". Indolymaleimides of LCTA series, provided by Prof. M.N. Preobrazhenskaya, were described earlier [20].

ther studies we used *E. coli* APHVIII146-1/Pk25 cells. For test system validation, we employed the previously described indolymaleimide STPK inhibitors LCTA-1385, LCTA-1398, LCTA-1425 [20], and Bis-1 [52] (Table 4). The standard concentration of kanamycin was 5 mg/disc, causing the appearance of a 10-mm zone of growth inhibition. All investigated compounds lowered kanamycin resistance. Substances from the indolymaleimide library (LCTA-1033, LCTA-1196, Bis-5) that did not exhibit inhibitory activity in *S. lividans* TK24 (66) APHVIII/STPK [20] showed no effect in the *E. coli* APHVIII146-1/Pk25-based test system that confirms the relevance of the latter.

DISCUSSION

Perspectives of application of *E. coli* APHVIII146-1/Pk25-based test system in screening for STPK inhibitors

The proposed test system can be used in prescreening for ATP-competitive low molecular weight inhibitors [2] that are able to diffuse in an agar-based medium, permeate through the *E. coli* cell wall, and interact with the adenine binding site of Pk25. The selectivity of the inhibitors depends on their affinity to adenine binding

pocket of the kinase. IFunctional similarity of the amino acid sequences leads to the similarity of the three-dimensional structures. This is also applicable in the case of the ligand binding sites that are responsible for the selectivity of inhibitors [55, 56].

The alignment of the amino acid sequence of the Pk25 catalytic domain with the catalytic domains of other bacterial STPKs, including those from pathogenic microorganisms performed in Genomic BLAST (http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi), revealed 13 proteins that share more than 35% identity. Among them are STPKs from *Mycobacterium*, *Staphylococcus*, *Streptococcus*, and *Pseudomonas*. Comparison of Pk25 with human STPKs revealed 19 proteins with more than 30% identity, including kinases from the SAD, BR, NUAk (SNF), DAPK3, PNCK, CAMKII, CAMKI, Zip, PKA, HUNK, PAK2, Mark-PAR1, SIK2, and OPK NimA families.

STPK inhibitors compete with ATP for the binding site and interact with the adenine binding pocket of the ATP binding site, which contains conservative and variable amino acid residues. We classified STPKs of gram-positive bacteria [23, 57] based on the physico-chemical properties of the sidechains of 9 variable amino acids in

Table 5. Ligand-binding amino acid residues of adenine-binding pocket of bacterial and human serine-threonine protein kinases.

Protein kinase	Functions of kinases in pathogenesis and physiology	Amino acids of the binding pocket	Effect of substitution
Bacterial STPKs			
Pk25 <i>S. coelicolor</i>	Modulation of resistance of aph-gene	LVA <u>V</u> MLVL T	Original
PknA <i>M. tuberculosis</i>	Synthesis of cell wall	<u>I</u> VA <u>I</u> MLVL T	Non-essential
PknJ <i>M. tuberculosis</i>	Persistence in the host	LVA <u>I</u> MFVL <u>S</u>	»
Stk1 <i>Streptococcus agalactiae</i>	Gerulation of intracellular segregation of GBS and virulence	<u>I</u> VA <u>I</u> MYVL T	»
StkP <i>S. pneumonia</i>	A fragment of signal pathway involved in lung and blood invasion	<u>I</u> VA <u>I</u> MYVL T	»
SP-STK <i>S. pyogenes</i>	Cell division, colony morphology, virulence	<u>I</u> VA <u>I</u> MYVL T	»
PpkA <i>P. aeruginosa</i>	Regulation of expression of virulence factors	LVA <u>T</u> MYLL <u>S</u>	Essential
PknB/Stk1 <i>Staphylococcus aureus</i> subsp. <i>aureus</i>	Regulation of purine biosynthesis, autolysis, core metabolism pathways	LVA <u>I</u> MY <u>I</u> L <u>F</u>	»
PknB <i>M. tuberculosis</i>	Cell division, inhibition of lysosome fusion	LVA <u>I</u> MY <u>V</u> M <u>M</u>	»
Homo sapiens STPK			
PKA <i>H. sapiens</i>	Allergy, myocardial disorders	LVA <u>L</u> MYVL T	Non-essential
CaMK ID <i>H. sapiens</i>	Type II diabetes	LVA <u>I</u> MLVL <u>S</u>	»
Pac2 <i>H. sapiens</i>	UV-caused epidermis diseases	<u>I</u> VA <u>I</u> MYLL T	»
BR kin1 <i>H. sapiens</i>	Regulation of cellular homeostasis	LVA <u>V</u> <u>L</u> HVL <u>A</u>	Essential
NUAK SNF1-11 <i>H. sapiens</i>	Modulation of TNF-alpha in cancer cells	LVA <u>I</u> MY <u>A</u> L <u>A</u>	»
CaMKII <i>H. sapiens</i>	Induction of long-termed synaptic memory	LVA <u>I</u> MY <u>A</u> L <u>A</u>	»

Note. Table represents serinen-threonine kinases containing no more than four amino acid substitutions in ligand-binding sequence LVAVMLVLT Pk25. Non-essential amino-acid substitutions are marked (–), while essential substitutions are marked (=), substitutions in the gatekeeper region are marked (–). Selectivity of inhibitors is determined by their affinity to the 9 amino acid motifs of the adenin-binding pocket of STPKs.

the adenine binding pocket of the catalytic domain. In this work, we used this classification to select STPKs of pathogenic bacteria that can be inhibited by the compounds selected in the proposed *E. coli* APHVIII/Pk25 test system. Table 5 contains 9 of the 13 potential ligand binding motifs of STPKs from pathogenic bacteria and 6 of the 19 motifs of human STPKs. The selection was based on the presence of no more than 4 out of 9 amino acid substitutions in variable positions of the adenine-binding pocket of Pk25 *S. lividans* (*S. coelicolor*) LVAVMLVLT. Substitutions of nonpolar amino acids by polar ones at the first four positions, as well as in position

8 (double underlined), were considered essential. All substitutions (except for the introduction of a similar amino acid) in position 9 (double underlined), and any substitutions in position 5 gatekeeper (underlined), were also considered essential. Substitutions in the hinge region (position 7 and in position 6) are less essential. Nonessential substitutions were underlined. The presence of two out of four nonessential substitutions does not alter the interaction mode of inhibitors with the adenine binding site of the protein kinase. Therefore, Pk25 can serve as a tool for the selection of inhibitors for 5 of the 13 STPKs from pathogenic bacteria and 3 of the 19 human STPKs.

The principle of structural similarity of the adenine binding pockets is a more reliable criterion than homology of the sequences of the whole catalytic domain.

In conclusion, the proposed test system can be used in prescreening for inhibitors of STPKs from some pathogenic microorganisms such as PknA, PknJ from

M. tuberculosis, StkP from *S. pneumonia*, SP-STK from *S. pyogenes*, as well as some human STPKs, e.g. PKA, CaMkinase1, and Pac2. ●

This work was supported by the Russian Foundation for Basic Research (grant № 09-04-12025).

REFERENCES

- Manning G., Whyte D.B., Martinez R., et al. // *Science*. 2002. V. 298. P. 1912–1934.
- Cohen P. // *Nat. Rev. Drug Discov.* 2002. V. 1. P. 309–315.
- Levitzi A. // *Acc. Chem. Res.* 2003. V. 36. P. 462–469.
- D'Alessandris C., Lauro R., Presta I., Sesti G. // *Diabetologia*. 2007. V. 50(4). P. 840–849.
- Barbier E., Zapata A., Oh E., et al. // *Neuropsychopharmacology*. 2007. V. 32(8). P. 1774–1782.
- Shirai H., Autieri M., Eguchi S. // *Curr. Opin Nephrol. Hypertens.* 2007. V. 16(2). P. 111–115.
- Collins I., Workman P. // *Nat. Chem. Biol.* 2006. V. 2. P. 689–700.
- Ishida A., Kameshita I., Sueyoshi N., et al. // *J. Pharmacol. Sci.* 2007. V. 103(1). P. 5–11.
- Goldstein D.M., Gray N.S., Zarrinkar P.P. // *Nat. Rev. Drug Discov.* 2008. V. 7. P. 391–397.
- Bain J., Plater L., Elliott M., et al. // *Biochem. J.* 2007. V. 408. P. 297–315.
- Liu Y., Gray N.S. // *Nat. Chem. Biol.* 2006. V. 2. P. 358–364.
- Shi L., Potts M., Kennelly P.J. // *FEMS Microbiol. Rev.* 1998. V. 22. P. 229–253.
- Echenique J., Kadioglu A., Romao S., et al. // *Infect. Immun.* 2004. V. 72(4). P. 2434–2437.
- Cozzone A.J. // *J. Mol. Microbiol. Biotechnol.* 2005. V. 9. P. 198–213.
- Pérez J., Garcia R., Bach H., et al. // *Biochem. Biophys. Res. Commun.* 2006. V. 348(1). P. 6–12.
- Drews S.J., Hung F., Av-Gay Y. // *FEMS Microbiol. Lett.* 2001. V. 205(2). P. 369–374.
- Saini D.K., Tyagi J.S. // *J. Biomol. Screen.* 2005. V. 10(3). P. 215–224.
- Wehenkel A., Bellinzoni M., Graña M., et al. // *Biochim. Biophys. Acta*. 2008. V. 1784(1). P. 193–202.
- Wázquez F., Szabadkai I., Németh G., et al. // *Immunol. Lett.* 2008. V. 116(2). P. 225–231.
- Danilenko V.N., Simonov A.Y., Lakatosh S.A., et al. // *J. Med. Chem.* 2008. V. 51. P. 7731–7736.
- Elizarov, S. M., Sergienko, O. V., Sizova, I. A., et al. // *Mol. Biologia (Molecular Biology)*, 2005. V. 35. P. 226–233.
- Bekker, O. B., Elizarov, S. M., Alekseeva, M. T., et al. // *Mikrobiologia (Microbiology)*. 2008. V. 75 (5). P. 559–567.
- Danilenko V.N., Osolodkin D.I., Lakatosh S.A., et al. // *Current Top. Med. Chemistry*. 2010. *In press*.
- Kieser T., Bibb M.J., Buttner M.J., et al. *Practical Streptomyces Genetics*. Norwich, John Innes Foundation. England, 2000. P. 613.
- Sambrook J., Fritsch E.F., Maniatis T. *Molecular Cloning: A Laboratory Manual*. 2nd ed. Cold Spring Harbor, N.Y.; Cold Spring Harbor Lab. Press, 1989.
- Kameshita I., Fujisawa H. // *Anal. Biochem.* 1989. V. 183. P. 139–143.
- Nelson R.M., Long G.L. // *Anal. Biochem.* 1989. V. 180. P. 147–151.
- Berman H.M., Westbrook J., Feng Z., et al. // *Nucleic Acids Research*. 2000. V. 28. P. 235–242.
- Young T.A., Delagoutte B., Endrizzi J.A., et al. // *Nat. Struct. Biol.* 2003. V. 10. P. 168–174.
- Ortiz-Lombardía M., Pompeo F., Boitel B., Alzari P.M. // *J. Biol. Chem.* 2003. V. 278. P. 13094–13100.
- Wehenkel A., Fernandez P., Bellinzoni M., et al. // *FEBS Lett.* 2006. V. 580. P. 3018–3022.
- Mieczkowski C., Iavarone A.T., Alber T. // *EMBO J.* 2008. V. 27. P. 3186–3197.
- Bentley S.D., Chater K.F., Cerdeno-Tarraga, et al. // *Nature*. 2002. V. 417. P. 141–147.
- Larkin M.A., Blackshields G., Brown N.P. // *Bioinformatics*. 2007. V. 23. P. 2947–2948.
- Šali A., Blundell T.L. // *J. Mol. Biol.* 1993. V. 234. P. 779–815.
- Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. // *J. Appl. Cryst.* 1993. V. 26. P. 283–291.
- SYBYL 8.0, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.
- Fong D.H., Berghuis A.M. // *EMBO J.* 2002. V. 21. P. 2323–2331.
- Nurizzo D., Shewry S.C., Perlin M.H., et al. // *J. Mol. Biol.* 2003. V. 327. P. 491–506.
- Huey R., Morris G.M., Olson A.J., Goodsell D.S. // *J. Comput. Chem.* 2007. V. 28. P. 1145–1152.
- Halgren T.A. // *J. Am. Chem. Soc.* 1990. V. 112. P. 4710–4723.
- Sanner M.F. // *J. Mol. Graphics Mod.* 1999. V. 17. P. 57–61.
- Umeyama T., Horinouchi S. // *Bacteriol.* 2001. V. 183. P. 5506–5512.
- Petrickova K., Tichy P., Petricek M. // *Biochem. Biophys. Res. Commun.* 2000. V. 279(3). P. 942–948.
- Scherr N., Müller P., Perisa D., et al. // *J. Bacteriol.* 2009. V. 191(14). P. 4546–4554.
- Villarino A., Duran R., Wehenkel A. // *J. Mol. Biol.* 2005. V. 350. P. 953–963.
- Taylor S.S., Yang J., Wu J., et al. // *Biochim. Biophys. Acta*. 2004. V. 1697(1–2). P. 259–269.
- Scheeff E.D., Bourne P.E. // *PloS Comput. Biol.* 2005. V. 1. P. 0359–0381.
- Nurizzo D., Shewry S.C., Perlin M.H., et al. // *J. Mol. Biol.* 2003. V. 327. P. 491–506.
- Durán R., Villarino A., Bellinzoni M. // *Biochem. Biophys. Res. Commun.* 2005. V. 333(3). P. 858–867.
- Alekseeva M., Elizarov S. // *Congress EurasiaBio-2010*, 13–15 apr. 2010, Moscow.
- Brehmer D., Godl K., Zech B., et al. // *Mol. Cell Proteomics*. 2004. V. 3(5). P. 490–500.
- Konings E.J.M., Roomans H.H.S. // *Food Chem.* 1997. V. 59. P. 599–603.
- Popov A.Y. Validation – what, where, when? // *Chistie pomeschenia i technologicheskie sredi (Clean placement and technological mediums)*, 2003. №3.
- Scherr N., Honnappa S., Kunz G., et al. // *Proc. Natl. Acad. Sci. USA*. 2007. V. 104. P. 12151–12156.
- Zakharevich N.V., Osolodkin D.I., Artamonova I.I., et al. // *Congress EurasiaBio-2010*, 13–15 apr. 2010, Moscow.